Poster Archives - Alzheon | Preserving Future Memories

2 Dec, 2019

APOE4/4 Subjects with Early Alzheimer’s Disease Show Accelerated Loss of Cortical Thickness and Cognitive Decline Compared to APOE3/3 Subjects

alzheon2019-11-27T16:57:28-05:00December 2nd, 2019|

24 Oct, 2018

APOE4/4 Early to Mild AD Subjects Show High Rates of Hippocampal Atrophy and Cognitive Decline in ADNI-1 and Tramiprosate Datasets

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

24 Oct, 2018

Clinical Effects of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses of Cognitive and Functional Outcomes

alzheon2019-09-23T12:10:47-04:00October 24th, 2018|

25 Jul, 2018

Clinical Benefits of Oral Tramiprosate in APOE4/4 Homozygotes with Mild Alzheimer’s Disease (AD): Responder Analyses from the Phase 3 North American Trial

alzheon2019-09-23T12:10:47-04:00July 25th, 2018|

2 Nov, 2017

Sustained Clinical Effects of Tramiprosate in APOE4/4 Homozygous Patients with Alzheimer’s Disease Over 130 Weeks: Results of Phase 3 Extension Study

alzheon2019-09-23T12:10:48-04:00November 2nd, 2017|

17 Jul, 2017

ALZ-801 Mechanism of Action: Stoichiometry of Beta Amyloid Anti-Oligomer Effect, PK/PD, and Clinical Dose Selection for Confirmatory Phase 3 Program in Alzheimer’s Disease

alzheon2019-09-23T12:10:49-04:00July 17th, 2017|

29 Mar, 2017

ALZ-801 Brain Penetration, PK/PD Analyses And Clinical Dose Projection Form The Basis For Confirmatory Phase 3 Study In Alzheimer’s Disease

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

29 Mar, 2017

Tramiprosate Efficacy in APOE4 Homozygous Subjects with AD: Larger Effects in Mild Patient Subgroups

alzheon2019-09-23T12:10:50-04:00March 29th, 2017|

9 Dec, 2016

Phase 1 Program of ALZ-801, a Novel Prodrug of Tramiprosate with Improved Tolerability, Supports Bridging to Upcoming Phase 3 Program

alzheon2019-09-23T12:10:50-04:00December 9th, 2016|

24 Jul, 2016

Clinically Meaningful Cognitive and Functional Improvements with Tramiprosate In Alzheimer’s Disease (AD) Patients with APOE4/4 Genotype: Subgroup Analyses from Two Phase 3 Studies

alzheon2019-09-23T12:10:52-04:00July 24th, 2016|